1. Introduction {#sec1}
===============

Diabetic macular edema (DME) is a common cause of visual loss in diabetic retinopathy (DR) and is a complication in any stages of DR including proliferative diabetic retinopathy (PDR) \[[@B1]\]. The current gold standard treatment for central-involving DME is intravitreal antivascular endothelial growth factor (anti-VEGF) therapy \[[@B2], [@B3]\]. However, tractional macular edema (TME) might be treated by vitrectomy with membrane removal since traction is not resolved by intravitreal anti-VEGF therapy \[[@B4]\]. Vitrectomy is also useful in some cases of diffuse nontractional macular edema (nTME) resistant to laser treatment or pharmacotherapy because vitrectomy improves oxygenation of the retina and diffusion of nutrients between the vitreous and retina \[[@B5]--[@B8]\].

Compared to the 20-gauge vitrectomy system, microincision transconjunctival sutureless vitrectomy systems decrease surgical invasion, shorten the operating time and duration of hospitalization, and lower the incidence of intra- and postoperative complications \[[@B9]--[@B11]\]. Vitrectomy combined with phacoemulsification and implantation of the intraocular lens is also effective for removal of peripheral vitreous gel and has advantages in some patients with PDR \[[@B12]\]. Furthermore, postoperative outcomes are further improved by preoperative adjunctive intravitreal anti-VEGF injection \[[@B13]\], internal limiting membrane peeling (ILMP) \[[@B14], [@B15]\], vitreous visualization using triamcinolone acetonide \[[@B16]\], and wide-angle viewing system \[[@B17]\].

Although previous studies have shown the benefit of vitrectomy for TME or nTME in diabetic retinopathy \[[@B18], [@B19]\], these studies had several limitations such as inclusion of various stages of diabetic retinopathy, use of the conventional 20-gauge vitrectomy system, small number of cases, retrospective design, and single-center study. In the present study, we compared real-world outcomes of visual acuity and anatomical restoration in the eyes with TME and nTME that underwent vitrectomy using current techniques and procedures and identified preoperative prognostic factors affecting postoperative visual acuity.

2. Materials and Methods {#sec2}
========================

This study was an observational case series of 116 eyes of 116 consecutive participants with type I (4 participants) or II (112 participants) diabetic mellitus who underwent primary 25-gauge vitrectomy for PDR with DME in six centers (National Defense Medical College Hospital; Hyogo College of Medicine Hospital; University of Fukui Hospital; Kagoshima University Hospital; Nara Medical University Hospital; and Tokyo Women\'s Medical University School of Medicine Diabetes Center) between April 2010 and March 2016. The study was conducted according to the tenets of the Declaration of Helsinki and was approved by institutional review board of each of the six hospitals. Inclusion criteria were as follows: (1) All participants had intravenous fluorescein angiograms before vitrectomy or after vitrectomy to confirm the diagnosis of PDR by two ophthalmologists. In cases with vitreous hemorrhage (VH) which obscures complete fundus observation before vitrectomy, two ophthalmologists confirmed the diagnosis of PDR by fundus observation and fluorescein angiograms after vitrectomy. (2) All participants were candidates for vitrectomy and signed a preoperative informed written consent form for the surgical procedure. (3) Participants with follow-up periods more than 12 months. Exclusion criteria were as follows: (1) participants with a follow-up period of less than 12 months, (2) other causes of proliferative vitreoretinal disease, (3) central retinal ischemia detected by intravenous fluorescein angiograms, (4) having a past history of vitrectomy, (5) having a past history of other retinal disease such as retinal vein occlusion and age-related macular degeneration, and (6) having a past history of any type of glaucoma.

All eyes were classified into TME group and nTME group. TME contained the proliferative membrane around the macula which attached the fovea and macular edema, while nTME lacked the proliferative membrane attaching to the fovea and macular edema. This classification was decided by at least 2 retinal specialists in each center at the primary vitrectomy based on preoperative fundus examination, color photographs, spectral domain-optical coherence tomography (SD-OCT) findings, and ultrasonography or intraoperative findings as described previously \[[@B20], [@B21]\].

2.1. Surgical Procedures and Postoperative Treatment {#sec2.1}
----------------------------------------------------

All eyes underwent 25-gauge vitrectomy using a wide-angle viewing system. In brief, the posterior vitreous was separated from the retina by active aspiration with the vitrectomy probe, and all visible vitreous strands that adhered to the retina were removed. Intravitreal triamcinolone acetonide (40 mg/mL, MaQaid; Wakamoto pharmaceutical Co., Tokyo, Japan) was systematically used in all cases to facilitate visualization and removal of the adherent posterior cortical vitreous. ILMP was systematically performed by staining the ILM with brilliant blue *G* followed by removal. Eyes with insufficient previous panretinal photocoagulation received additional intraoperative panretinal photocoagulation. No eye had received intravitreal anti-VEGF injection or intravitreal/subtenon triamcinolone acetonide injection at the end of vitrectomy. After vitrectomy, topical antibiotic and anti-inflammatory agents were administered 4 times daily for 1 month, and postoperative additional treatments, i.e., revitrectomy, intravitreal anti-VEGF injection, subtenon triamcinolone acetonide (STTA) injection, and cataract surgery, were performed by the clinician\'s decision, but no eye had received intravitreal triamcinolone acetonide injection.

2.2. Measurement of Visual Acuity, Intraocular Pressure, and Retinal Structure {#sec2.2}
------------------------------------------------------------------------------

At each visit, the patients underwent a complete ophthalmologic examination including best-corrected visual acuity, refractive measurement, SD-OCT, intraocular pressure measurement, slit-lamp examination, and dilated fundus examination (using contact and noncontact fundus lenses). Visual acuity was measured using the standard Japanese decimal visual acuity chart, and the values were converted to logarithm of the minimum angle of resolution (LogMAR) units for data analysis, as described previously \[[@B22]\]. Intraocular pressure was measured by noncontact tonometry or Goldmann applanation tonometer, and ocular hypertension was defined as intraocular pressure \>21 mmHg. SD-OCT scans were performed preoperatively to measure the retinal thickness and to evaluate the presence of macular edema and/or macular traction. Central macular thickness (CMT) measurements were read from the automated measurements generated by the machine using the retinal map analysis protocol.

2.3. Comparison of Ocular Factors and General Factors {#sec2.3}
-----------------------------------------------------

Baseline general conditions (age, sex, diabetic duration, HbA1c, estimated glomerular filtration rate (eGFR), systemic hypertension, and anticoagulant therapy), baseline ocular conditions (LogMAR, CMT, phakia or pseudophakia, ocular hypertension, vitreous hemorrhage, preoperative adjunctive intravitreal anti-VEGF injection, and retinal photocoagulation), surgical procedures (combined phacoemulsification, retinal break, and tamponade material), postoperative complications (vitreous hemorrhage, neovascular glaucoma, and cataract formation), and postoperative additional treatments (revitrectomy, intravitreal anti-VEGF injection, and STTA) were evaluated. HbA1c is expressed in the National Glycohemoglobin Standardization Program (NGSP) unit \[[@B23]\]. Hypertension was defined as use of the antihypertension agent or diagnosed by physicians in each hospital.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Results are expressed as mean ± standard deviation with range \[low--high\] for continuous variables. The Mann--Whitey *U* test and chi-square test were used to compare the data between the two groups, and repeated measures ANOVA and the Bonferroni correction were used to compare the changes in LogMAR and CMT in the group. Multiple linear regression analysis was used to detect the correlation between the change in LogMAR and other factors. A *P* value less than 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Participants and Treatment {#sec3.1}
-------------------------------

Baseline characteristics, surgical procedures, and postoperative complications and additional treatments in TME and nTME groups are shown in [Table 1](#tab1){ref-type="table"}.

The TME group consisted of 56 eyes of 56 patients (36 males; mean age 57.8 ± 9.5 years \[38--74\]), and the nTME group comprised 60 eyes of 60 patients (36 males; mean age 58.7 ± 14.1 years \[30--81\]). There were significant differences in vitreous hemorrhage (*P* \< 0.001) but no significant differences in baseline general conditions between two groups. In surgical procedures, combined cataract surgery was performed more frequently in the TME group than that in the nTME group (*P* \< 0.001). However, the eyes with intraocular lens (IOL) were 50 eyes in the TME group and 47 eyes in the nTME group at 12 months after vitrectomy, and statistical difference was not observed between the two groups. In postoperative complications, 13 eyes (8 eyes in the TME group and 5 eyes in the nTME group) underwent revitrectomy, and 5 eyes (1 eye in the TME group and 4 eyes in the nTME group) developed postoperative NVG. In additional treatment, 2 eyes (3 months and 10 months after vitrectomy) received intravitreal anti-VEGF injection and 10 eyes (7 eyes at 1 month, 2 eyes at 4 months, and 1 eye at 6 months after vitrectomy) received STTA injection in the TME group, and 4 eyes (1 eye at 1 month, 1 eye at 3 months, and 2 eyes at 6 months after vitrectomy) received intravitreal anti-VEGF injection and 3 eyes at 1 month after vitrectomy received STTA injections in the nTME group.

3.2. Visual and Anatomical Results {#sec3.2}
----------------------------------

Mean LogMAR in the TME group and nTME group improved significantly from 1.05 ± 0.71 \[2.7--0\] and 1.26 ± 0.74 \[2.7--0.05\], respectively, at baseline to 0.66 ± 0.65 \[2.7 to −0.08\] and 0.48 ± 0.55 \[2.3 to −0.08\] (both *P* \< 0.001) at 6 months, and 0.69 ± 0.78 \[3.0 to −0.08\] and 0.36 ± 0.41 \[1.5 to −0.08\] (both *P* \< 0.001) at 12 months ([Figure 1(a)](#fig1){ref-type="fig"}).

The mean visual improvement in the TME group and nTME group was 0.39 LogMAR (corresponding to a mean increase of 3.9 lines) and 0.78 LogMAR (mean increase of 7.8 lines), respectively, from baseline to 6 months, −0.03 LogMAR (mean decrease of 0 lines) and 0.12 LogMAR (mean increase of 1.2 lines) from 6 months to 12 months, and 0.36 LogMAR (mean decrease of 3.6 lines) and 0.90 LogMAR (mean increase of 9.0 lines) from baseline to 12 months, respectively ([Figure 1(b)](#fig1){ref-type="fig"}). In the TME group, LogMAR improved by more than 2 lines in 23 (41.1%) eyes, did not change by more than 2 lines in 24 eyes (42.9%), and worsened by more than 2 lines in 9 eyes (16.1%) ([Figure 1(c)](#fig1){ref-type="fig"}). In the nTME group, LogMAR improved by more than 2 lines in 47 (78.3%) eyes, did not change by more than 2 lines in 12 eyes (20.0%), and worsened by more than 2 lines in 1 eye (1.7%) ([Figure 1(d)](#fig1){ref-type="fig"}). Comparing 2-line LogMAR improvement, there was significant difference between two groups (*P* \< 0.001).

However, when LogMAR improvement from baseline to 12 months was compared in two groups, there was no significant difference (*P*=0.058). Subsequently, we evaluated the differences between eyes with and without visual improvement in TME and nTME groups ([Table 2](#tab2){ref-type="table"}).

In the TME group, there were significant differences in baseline LogMAR (*P*=0.003), CMT (*P*=0.005), and VH (*P*=0.019) between improved and nonimproved eyes. In the nTME group, there were significant differences in baseline LogMAR (*P*=0.001) and VH (*P*=0.037). We then evaluated the differences between LogMAR at 12 months better and worse than 1.0 ([Table 3](#tab3){ref-type="table"}).

In the TME group, eyes with LogMAR better than 1.0 (*n* = 40) had better baseline LogMAR (*P*=0.002) than eyes with LogMAR worse than 1.0 (*n* = 16). In the nTME group, eyes with LogMAR better than 1.0 (*n* = 51) were younger (*P*=0.0017), had shorter diabetic duration (*P* = 0.0069), and had better baseline LogMAR (*P*=0.039) than eyes with LogMAR worse than 1.0 (*n* = 9).

Mean CMT in the TME group and nTME group decreased significantly from 467 ± 200 \[150--1008\] and 410 ± 133 \[148--998\] *μ*m, respectively, at baseline to 291 ± 129 \[109--707\] and 292 ± 99 *μ*m \[135--610\] (both *P* \< 0.01) at 6 months and 259 ± 109 \[195--610\] and 277 ± 110 *μ*m \[101--700\] (both *P* \< 0.01) at 12 months ([Figure 1(e)](#fig1){ref-type="fig"}). The mean percent CMT reduction in the TME group and nTME group was 29.0% and 22.9%, respectively, from baseline to 6 months, 7.5% and 2.9% from 6 months to 12 months, and 29.0% and 22.9% from baseline to 12 months ([Figure 1(f)](#fig1){ref-type="fig"}). There was a no significant difference in postoperative improvement of CMT between the two groups.

3.3. Prognostic Factors for 12-Month Visual Acuity {#sec3.3}
--------------------------------------------------

We conducted multiple linear regression analyses to examine the relationship between LogMAR at 12 months and baseline LogMAR or VH in the TME group and baseline LogMAR, diabetic duration, VH, and eGFR in the nTME group, which might affect postoperative LogMAR in the TME group and nTME group (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}) and age and sex from general condition. A positive correlation with baseline LogMAR (*P*=0.001, 95% confidence interval (CI): 0.24--0.75) and baseline CMT (*P*=0.031, 95% CI: 0.000--0.002) and negative correlation between VH (*P*=0.039, 95% CI: −0.75--0.02) were observed in the TME group, while a positive correlation with diabetic duration (*P*=0.017, 95% CI: 0.002--0.023) and a negative correlation with eGFR (*P*=0.003, 95% CI: −0.007--0.002) were observed in the nTME group ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

The present study found no significant differences in the improvement of LogMAR and reduction of CMT after microincision transconjunctival sutureless vitrectomy with ILMP between TME and nTME in the eyes with PDR. Approximately 40% of TME patients and 80% of nTME patients had visual gain of more than 2 lines at 12 months. Furthermore, no significant differences in surgical complications were found between TME and nTME. Finally, baseline LogMAR and CMT in TME and baseline LogMAR and kidney function in nTME were identified as independent predictive factors of the final LogMAR.

The effectiveness of vitrectomy for tractional DME was demonstrated by Lewis et al. \[[@B24]\] in 1992 and was confirmed by further prospective studies. The <http://DRCR.net> prospective study on vitrectomy outcomes in the eyes with diabetic macular edema and vitreomacular traction reported significant visual improvement in 38% and significant visual deterioration in 22% of the subjects \[[@B4]\]. In the present study, vitrectomy with ILMP was performed for TME or nTME involved in eyes in which PDR was evaluated, and the DME eyes with non-PDR eyes were excluded. Visual improvement and deterioration in tractional DME were 23 eyes (41.1%) versus 9 eyes (16.1%), which was similar to the results of the <http://DRCR.net> prospective study \[[@B4]\]. However, LogMAR improvement was achieved by resolving both DME and various preoperative complications in this study. For instance, preoperative VH, which could account for visual disturbance, was observed in 52 eyes, and combined cataract surgery was performed in 36 eyes out of 60 eyes with nTME. Although multiple linear regression analysis showed no significant correlation between 12-month LogMAR and preoperative VH and combined cataract surgery, these could be considered as the causes that mean visual improvement at 12-month follow-up in both groups was higher than previous studies of vitrectomy with ILMP on DME \[[@B4], [@B24]\].

In clinical situation, there is a good deal of evidence suggesting that vitrectomy effectively restores retinal function and significantly decreases macular edema. Lewis et al. reported that vitrectomy was effective in the eyes with macular edema associated with a thickened and taut posterior hyaloid membrane \[[@B24]\]. Although the role of vitrectomy in the treatment of DME remains not to be fully elucidated, several physiopathologic mechanisms have been suggested to explain the favorable results obtained with vitrectomy in the nTME eyes. Vitrectomy removes vitreous cortex adjacent to the retina, improves retinal oxygenation, eliminates inflammatory cells, and reduces inflammatory cytokines and proangiogenic factors such as VEGF that induces DME \[[@B25], [@B26]\]. In this study, all eyes underwent ILMP. The rationale for this procedure is that ILMP allows complete removal of overlying residual vitreous cortex and inflammatory cells adhering to the inner surface of the ILM \[[@B27], [@B28]\].

Vitrectomy for PDR is associated with certain complications, including postoperative VH, cataracts progression, IRT, retinal detachment, and NVG \[[@B9], [@B13], [@B19]\]. Postoperative VH is a most frequent complication, and Wakabayashi reported the percentage of postoperative VH in 60 PDR eyes during 6-month follow-up was 25% \[[@B29]\], and Ozone reported that percentage of postoperative VH was 22% \[[@B30]\]. NVG is the most severe complication following vitrectomy. Kumagai and Yamamoto reported the incidence of developing postoperative NVG were 3.9% and 4.6% \[[@B5], [@B31]\]. In the present study, postoperative VH was 27 eyes (23%) and NVG was 6 eyes (5.1%) that were compatible with those of previous reports. On the contrary, it was reported that more than one-half of phakic eyes developed cataract in conventional vitrectomy for DME \[[@B18]\]. However, visual disturbance by cataract progression is avoidable. In Japan, cataract surgery is often combined with vitrectomy to prevent the visual loss that occurs with progression of cataract \[[@B32]\]. As well as in this study, 85 eyes (73.3%) underwent combined cataract surgery. Except for 13 eyes (11.2%) which had undergone past cataract surgery, 18 eyes (15.6%) remained phakic; however, 5 of 18 phakia eyes (27.8%) needed additional cataract surgery within 6 months. This result might suggest that combined cataract surgery is preferable to prevent high proportion of postoperative cataract progression.

Renal dysfunction is associated with an increased likelihood of worsening diabetic retinopathy \[[@B33]\]. A retrospective study from the US which involves more than 4000 patients with diabetic retinopathy showed the presence of nephropathy increased the risk of progression to proliferative diabetic retinopathy \[[@B34]\]. Diabetic kidney dysfunction decreases the secretion of erythropoietin that causes chronic anemia and retinal tissue and cellular hypoxia \[[@B35]\], and kidney dysfunction is known to be a risk factor for developing diabetic retinopathy \[[@B36]\] and DME \[[@B37]\]. Management of diabetic retinopathy in patients at risk of severe acute renal impairment should follow more strict and aggressive rules \[[@B38]\]. In the present study, multiple linear regression analysis identified kidney function as a factor negatively correlated with postoperative visual function in the nTME group, consistent with previous report \[[@B37]\]. This multicenter study also demonstrates kidney function as an important factor for diabetic retinopathy.

In the surgical procedure, all eyes had received intravitreal triamcinolone injection and many eyes had additional retinal photocoagulation. Intravitreal triamcinolone and retinal photocoagulation had some effects for the postoperative retinal structure and even visual outcomes in short term and would not continue after 6 months. Additional anti-VEGF and STTA injections were performed in 19 eyes. In the two groups, anti-VEGFs were performed at 1 month, 3 months, 6 months, and 10 months after vitrectomy. STTA injections were performed at 1 month, 3 months, and 6 months. In general, these treatments present immediate effects and do not continue for a long time. However, it is possible that the efficacy might affect the visual and anatomical outcomes at 6 months or 12 months in some cases.

This study has several limitations. The major limitation is the retrospective multicenter comparative study without any control group although all surgical procedures were performed under similar conditions. Baseline factors which affect postoperative LogMAR, such as lens status, anti-VEGF and STTA injections, and VH, were evaluated although macular degeneration or optic nerve atrophy could not be standardized or excluded. A second limitation is that only Japanese subjects were studied and both type 1 and type 2 diabetes mellitus were included. Finally, the absence of difference between the two groups may be simply attributable to the lack of statistical power in this study or to selection bias.

5. Conclusion {#sec5}
=============

This study confirmed the functional and anatomical efficacy of vitrectomy for both tractional and nontractional DME in PDR eyes, without severe surgical complications. The real-world outcomes obtained from this multicenter study are more reliable than previous single-center studies. The high and increasing prevalence of DME and the existence of nonresponders to anti-VEGF therapy require consideration of alternative therapies such as vitrectomy that may improve diabetic patient care.
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###### 

Baseline characteristics, surgical procedures, and postoperative complications and additional treatments in the two groups.

                                                          TME                        nTME                        *P*
  ------------------------------------------------------- -------------------------- --------------------------- ---------
  Baseline general conditions                                                                                    
   Eyes                                                   56                         60                           
   Mean age (year)                                        57.8 ± 9.5 \[38--74\]      58.7 ± 14.1 \[30--81\]      0.20
   Sex (male/female)                                      36/20                      36/24                       0.63
   Diabetic duration (years)                              12.4 ± 11.7 \[1--41\]      10.6 ± 9.2 \[1--46\]        0.38
   HbA1c (%)                                              7.6 ± 1.7 \[5.3--13.3\]    7.9 ± 1.5 \[4.8--11.8\]     0.26
   eGFR (ml/m)                                            54.9 ± 33.0 \[0.5--112\]   58.8 ± 36.8 \[0.5--111\]    0.25
   Hypertension                                           34                         43                          0.21
   Anticoagulant use                                      7                          4                           0.45
                                                                                                                 
  Baseline ocular conditions                                                                                     
   Mean LogMAR                                            1.05 ± 0.71 \[2.7--0\]     1.26 ± 0.74 \[2.7--0.05\]   0.06
   Mean CMT (*μ*m)                                        467 ± 200 \[150--1008\]    410 ± 133 \[148--998\]      0.06
   Lens status (IOL/phakia)                               3/53                       10/50                       0.10
   Ocular hypertension                                    4                          1                           0.32
   Vitreous hemorrhage                                    31                         52                          \<0.001
   Tractional retinal detachment                          11                         5                           0.13
   Adjunctive intravitreal anti-VEGF injection            16                         11                          0.19
   Retinal photocoagulation                               39                         46                          0.39
                                                                                                                 
  Surgical procedures                                                                                            
   Combined cataract surgery                              49                         36                          \<0.001
   Retinal break                                          17                         9                           0.079
   Tamponade (air/gas/silicon oil)                        18/8/1                     16/6/0                      0.54
                                                                                                                 
  Postoperative complications and additional treatments                                                          
   Vitreous hemorrhage                                    13                         14                          0.99
   Neovascular glaucoma                                   2                          4                           0.40
   Cataract progression                                   1                          4                           0.21
   Revitrectomy                                           8                          5                           0.47
   Intravitreal anti-VEGF injection                       2                          4                           0.74
   Subtenon steroid injection                             10                         3                           0.057

Data are expressed as number of eyes or patients or mean ± standard deviation \[low--high\].

###### 

Comparison of the eyes with and without visual acuity improvement in the two groups.

                                                  Improvement                 No improvement              *P*
  ----------------------------------------------- --------------------------- --------------------------- ---------
  TME group                                       23 eyes                     33 eyes                      
   Baseline general conditions                                                                             
    Mean age (year)                               55.5 ± 9.4 \[38--69\]       59.0 ± 9.2 \[40--74\]       0.09
    Sex (male/female)                             12/11                       24/9                        0.19
    Diabetic duration (year)                      11.0 ± 11.0 \[1--30\]       12.5 ± 12.3 \[1--41\]       0.27
    HbA1c (%)                                     7.4 ± 1.9 \[5.3--11.6\]     7.9 ± 1.7 \[6.4--13.3\]     0.059
    eGFR (ml/m)                                   55.0 ± 28.7 \[0.93--96\]    56.7 ± 35.8 \[0.5--112\]    0.48
    Hypertension                                  16                          18                          0.26
    Anticoagulant use                             5                           2                           0.18
   Baseline ocular conditions                                                                              
    Mean LogMAR                                   1.34 ± 0.65 \[2.7--0.2\]    0.83 ± 0.70 \[2.7--0\]      0.003
    Mean CMT (*μ*m)                               603 ± 162 \[356--801\]      413 ± 195 \[150--1008\]     0.005
    Lens status (IOL/phakia)                      0/23                        3/30                        0.25
    Ocular hypertension                           1                           3                           0.38
    Vitreous hemorrhage                           17                          14                          0.019
    Tractional retinal detachment                 6                           5                           0.31
    Adjunctive intravitreal anti-VEGF injection   8                           8                           0.58
    Retinal photocoagulation                      14                          25                          0.23
                                                                                                          
  nTME group                                      47 eyes                     13 eyes                      
   Baseline general conditions                                                                             
    Mean age (year)                               57.9 ± 13.9 \[30--77\]      61.8 ± 15.0 \[42--81\]      0.18
    Sex (male/female)                             27/20                       9/4                         0.65
    Diabetic duration (years)                     9.5 ± 8.3 \[1--30\]         14.7 ± 14.1 \[1--46\]       0.18
    HbA1c (%)                                     8.0 ± 1.8 \[4.8--11.8\]     7.5 ± 1.0 \[6.4--10.2\]     0.19
    eGFR (ml/m)                                   61.6 ± 41.0 \[0.5--111\]    66.1 ± 40.8 \[0.55--110\]   0.32
    Hypertension                                  33                          10                          0.90
    Anticoagulant use                             3                           1                           0.64
   Baseline ocular conditions                                                                              
    Mean LogMAR                                   1.47 ± 0.67 \[2.7--0.22\]   0.51 ± 0.45 \[1.4--0.05\]   \<0.001
    Mean CMT (*μ*m)                               429 ± 186 \[148--811\]      363 ± 97 \[242--988\]       0.19
    Lens status (IOL/phakia)                      12/35                       2/11                        0.69
    Ocular hypertension                           1                           0                           0.21
    Vitreous hemorrhage                           43                          9                           0.037
    Tractional retinal detachment                 4                           1                           0.92
    Adjunctive intravitreal anti-VEGF injection   10                          1                           0.06
    Retinal photocoagulation                      36                          10                          0.98

Data are expressed as number of eyes or patients or mean ± standard deviation \[low--high\].

###### 

Comparison of eyes with 12 months LogMAR better versus worse than 20/200 in the two groups.

                                                  Better                      Worse                       *P*
  ----------------------------------------------- --------------------------- --------------------------- --------
  TME group                                       40 eyes                     16 eyes                      
   Baseline general conditions                                                                            
    Mean age (year)                               57.8 ± 9.3 \[38--74\]       57.8 ± 10.1 \[40--70\]      0.13
    Sex (male/female)                             24/16                       12/4                        0.45
    Diabetic duration (years)                     12.0 ± 11.7 \[1--41\]       13.5 ± 13.7 \[1--40\]       0.29
    HbA1c (% (mmol/mol))                          7.8 ± 2.1 \[5.3--13.3\]     7.4 ± 0.9 \[5.6--9.3\]      0.13
    eGFR (ml/m)                                   55.4 ± 34.8 \[0.61--112\]   53.8 ± 30.0 \[0.5--101\]    0.47
    Hypertension                                  27                          7                           0.18
    Anticoagulant use                             4                           3                           0.65
   Baseline ocular conditions                                                                             
    Mean LogMAR                                   0.87 ± 0.68 \[2.7--0\]      1.50 ± 0.60 \[2.7--0.52\]   0.002
    Mean CMT (*μ*m)                               475 ± 154 \[227--801\]      451 ± 290 \[150--1008\]     0.16
    Lens status (IOL/phakia)                      1/39                        2/14                        0.19
    Ocular hypertension                           2                           2                           0.57
    Vitreous hemorrhage                           24                          7                           0.41
    Tractional retinal detachment                 7                           4                           0.52
    Adjunctive intravitreal anti-VEGF injection   11                          5                           0.96
    Retinal photocoagulation                      27                          12                          0.58
                                                                                                          
  nTME group                                      51 eyes                     9 eyes                       
   Baseline general conditions                                                                            
    Mean age (year)                               56.4 ± 13.8 \[30--77\]      71.8 ± 7.5 \[58--81\]       0.0017
    Sex (male/female)                             30/21                       6/3                         0.66
    Diabetic duration (years)                     9.0 ± 8.3 \[1--30\]         23.0 ± 14.3 \[7--46\]       0.0069
    HbA1c (% (mmol/mol))                          8.0 ± 1.6 \[4.8--11.8\]     7.3 ± 1.4 \[6.0--10.2\]     0.13
    eGFR (ml/m)                                   66.2 ± 41.0 \[0.5--111\]    40.7 ± 31.7 \[0.6--71\]     0.06
    Hypertension                                  36                          6                           0.87
    Anticoagulant medication                      4                           1                           0.74
   Baseline ocular conditions                                                                             
    Mean LogMAR                                   1.18 ± 0.72 \[2.7--0.05\]   1.70 ± 0.70 \[2.7--1\]      0.039
    Mean CMT (*μ*m)                               408 ± 176 \[145--811\]      408 ± 105 \[247--501\]      0.42
    Lens status (IOL/phakia)                      8/43                        2/7                         0.63
    Ocular hypertension                           0                           1                           0.15
    Vitreous hemorrhage                           42                          6                           0.53
    Tractional retinal detachment                 3                           2                           0.10
    Adjunctive intravitreal anti-VEGF injection   10                          1                           0.89
    Retinal photocoagulation                      40                          6                           0.74

Data are expressed as number of eyes or patients or mean ± standard deviation \[low--high\].

###### 

Prognostic factors affecting visual acuity at 12 months after vitrectomy in the two groups.

                   Variable              Estimate   95% CI          *P*
  ---------------- --------------------- ---------- --------------- ---------
  TME group                                                         
   Adjusted        Age                   −0.005     −0.02--0.01     0.58
   *R*^2^ = 0.44   Sex                   −0.32      −0.68--0.03     0.07
   *P* \< 0.001    Baseline LogMAR       0.50       0.24--0.75      \<0.001
                   Vitreous hemorrhage   −0.38      −0.75--0.02     0.039
                   Baseline CMT          0.0012     0.000--0.002    0.031
                                                                    
  nTME group                                                        
   Adjusted        Age                   0.001      −0.006--0.008   0.78
   *R*^2^ = 0.42   Sex                   −0.029     −0.22--0.16     0.76
   *P* \< 0.001    Baseline LogMAR       0.097      −0.028--0.22    0.13
                   Diabetic duration     0.013      0.002--0.023    0.017
                   Vitreous hemorrhage   −0.25      −0.54--0.05     0.10
                   eGFR                  −0.004     −0.007--0.002   0.003

[^1]: Academic Editor: Tamer A. Macky
